2.2 63 Eligibility for HFrEF trials Table 1. Heart failure phase III trial characteristics Outpatient Hospitalized HF Total HFrEF HFpEF Any EF N (%) 163 43.5% 33 8.8% 114 30.4% 65 17.3% 375 100% Start year 1985-2005 42 25.8% 2 6.1% 23 20.2% 13 20.0% 80 21.3% 2006-2010 36 22.1% 7 21.2% 31 27.2% 16 24.6% 90 24.0% 2011-2015 48 29.4% 5 15.2% 27 23.7% 16 24.6% 96 25.6% 2016-2022 37 22.7% 19 57.6% 33 28.9% 20 30.8% 109 29.1% Trial size Median (IQR) 160 50, 402 336 52, 1490 130 51, 330 255 112, 654 170 54, 505 0-50 41 26.1% 8 24.2% 28 24.8% 11 16.9% 88 23.9% 51-100 26 16.6% 6 18.2% 21 18.6% 3 4.6% 56 15.2% 101-200 19 12.1% 0 0.0% 23 20.4% 13 20.0% 55 14.9% 201-500 36 22.9% 4 12.1% 18 15.9% 18 27.7% 76 20.7% 500+ 35 22.3% 15 45.5% 23 20.4% 20 30.8% 93 25.3% missing 6 0 1 0 7 Intervention type Drug 107 65.6% 32 97.0% 60 52.6% 60 92.3% 240 68.2% Device 33 20.2% 0 0% 27 23.7% 3 4.6% 60 17.0% Behavioural 11 6.7% 0 0% 17 14.9% 2 0% 29 8.2% Procedure/ Diagnostic 13 8.0% 1 3.0% 6 5.3% 1 3.1% 25 7.1% Biological 7 4.3% 0 0% 6 5.3% 0 0% 11 3.1% Dietary 2 1.2% 0 0% 4 3.5% 1 1.5% 5 1.4%
RkJQdWJsaXNoZXIy MjY0ODMw